Patent: 9,629,927
✉ Email this page to a colleague
Summary for Patent: 9,629,927
| Title: | Single wall nanotube constructs and uses thereof |
| Abstract: | The present invention provides soluble single wall nanotube (SWNT) constructs functionalized with a plurality of a targeting moiety and a plurality of one or more payload molecules attached thereto. The targeting moiety and the payload molecules may be attached to the soluble SWNT via a DNA or other oligomer platform attached to the SWNT. These soluble SWNT constructs may comprise a radionuclide or contrast agent and as such are effective as diagnostic and therapeutic agents. Methods provided herein are to diagnosing or locating a cancer, treating a cancer, eliciting an immune response against a cancer or delivering an anticancer drug in situ via an enzymatic nanofactory using the soluble SWNT constructs. |
| Inventor(s): | Scheinberg; David A. (New York, NY), McDevitt; Michael R. (Bronx, NY), Antczak; Christophe (Arlington, MA), Chattopadhyay; Debjit (Pennington, NJ), May; Rena (Baltimore, MD), Njardarson; Jon (Tucson, AZ), Phillips; Mark Reid (New York, NY) |
| Assignee: | Sloan-Kettering Institute for Cancer Research (New York, NY) |
| Application Number: | 14/034,503 |
| Patent Claims: | see list of patent claims |
Details for Patent 9,629,927
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Genentech, Inc. | RITUXAN | rituximab | Injection | 103705 | 11/26/1997 | ⤷ Try a Trial | 2025-07-29 |
| Idec Pharmaceuticals Corp. | RITUXAN | rituximab | Injection | 103737 | 02/19/2002 | ⤷ Try a Trial | 2025-07-29 |
| Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 09/25/1998 | ⤷ Try a Trial | 2025-07-29 |
| Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 02/10/2017 | ⤷ Try a Trial | 2025-07-29 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
